The emergence of antimicrobial resistance against Mycobacterium tuberculosis, the leading
cause of mortality due to a single microbial pathogen worldwide, represents a growing threat …

Improving treatment outcomes in multidrug‐resistant tuberculosis (MDR‐TB) is partly
hampered by inadequate effective antitubercular agents. Development of bedaquiline and …

The Comprehensive Resistance Prediction for Tuberculosis: an International Consortium
(CRyPTIC) presents here a data compendium of 12,289 Mycobacterium tuberculosis global …

The treatment of multidrug-resistant (MDR) or extensively drug-resistant (XDR) tuberculosis
(TB) remains a challenge for clinicians for several reasons, including the large number of …

Many bacterial pathogens can permanently colonize their host and establish either chronic
or recurrent infections that the immune system and antimicrobial therapies fail to eradicate …

Bedaquiline is recommended by the World Health Organization for the treatment of
multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB). We …

Background Understanding the impact of drug exposure and susceptibility on treatment
response of multidrug-resistant tuberculosis (MDR-TB) will help to optimise treatment. This …

Background At the end of 2018, South Africa updated its all-oral regimen, to include
bedaquiline (BDQ) and 2 months of linezolid (LZD) for all patients initiating the shorter 9–12 …

Relatively little is known about the efficacy and safety of the programmatic use of
bedaquiline and delamanid in multidrug-resistant tuberculosis (MDR-TB) treatment. This …

Tuberculosis (TB) is a major public health problem, with nearly 10 million new cases and
millions of deaths each year. Around 10% of these cases are in children, but only a fraction …